Belief BioMed

Belief BioMed (BBM) is a leading clinical-stage biotechnology company focused on the development and manufacturing of innovative adeno-associated virus (AAV) gene therapies. The company integrates R&D, clinical application, and large-scale manufacturing to address unmet medical needs in rare genetic disorders and chronic diseases. Its proprietary Capsidx® platform enables the design of tissue-specific AAV capsids with high transduction efficiency and low immunogenicity. In April 2025, Belief BioMed achieved a major milestone with the NMPA approval of BBM-H901, the first domestically developed hemophilia B gene therapy in China. The company has established a robust pipeline including candidates for Hemophilia A, Duchenne Muscular Dystrophy (DMD), and Parkinson's disease. BBM maintains a state-of-the-art 15,000 sqm manufacturing facility in Suzhou with a 2,000L production capacity, supporting its goal of providing affordable and accessible gene therapies globally.